Jacobio Pharmaceuticals (HKG:1167) said its cash runway extends at least four years, supported by about 2.10 billion yuan in cash and bank balances, capital-protected structured deposits, and available bank credit facilities, according to a Tuesday Hong Kong bourse filing.
The drug company said it has repurchased 747,800 shares for about HK$34.2 million as of May 18.
Jacobio also received a $100 million upfront payment from AstraZeneca under a strategic collaboration agreement, along with 8.6 million yuan in sales royalty payments from Allist for the June-to-December 2025 period, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments